Creso Pharma Ltd.’s stock surged up 3.9% on February 27, 2018 while the group announced about reporting first revenues in 2018 based on the launch of Creso’s cannaQIX® (first standardised nutraceutical containing organic hemp extract with CBD, vitamins and zinc) in March 2018 in Switzerland in collaboration with partner Doetsch Grether. The launch of the product has been highlighted to pave the path for Creso’s global commercialisation and will set the cornerstone for Creso Pharma’s global commercialisation strategy using Switzerland as a reference country.

Basis the performance, Creso reported for first revenues of CHF 230,000 (A$311,940) from cannaQIX® along with sales of Creso’s animal health product, anibidiol®. The marketing and distribution of cannaQIX® is based on an exclusive commercialisation agreement under which Doetsch Grether markets the products through its distribution channels.

On the global front, CPH is finalising access and distribution agreements in Europe and Latin America while Switzerland is intended to be used as international regulatory, quality and Market reference country. Creso had also formally entered Canadian market with the recent completion of Mernova acquisition. The group is expected to see a spurt of growth with rising demand for safe and reliable hemp-based products across the globe. It will be good to stick around with the stock looking at the efforts on growth and the industry trends.

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.